BioToday.com [新着ニュース] BioToday.comは医学情報、バイオテクノロジー、バイオベンチャー関連ニュースのデータベースです。 http://www.biotoday.com/news.cfm biotoday@biotoday.com Copyright © 2026 BioToday Ltd. All Rights Reserved. Tue, 01 Sep 2026 16:57:57 +0900 ja http://blogs.law.harvard.edu/tech/rss [医学] 動脈硬化疾患とされていない18-29歳若者の実に13人1人ほどが実は動脈硬化持ち http://www.biotoday.com/view.cfm?n=110564&ref=rss http://www.biotoday.com/view.cfm?n=110564&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Tue, 01 Sep 2026 16:57:55 +0900 http://www.biotoday.com/post_comment.cfm?init=A110564&ref=rss [企業] PharmaEssentiaのインターフェロン薬Besremiの血小板血症治療を米国承認 http://www.biotoday.com/view.cfm?n=110563&ref=rss http://www.biotoday.com/view.cfm?n=110563&ref=rss 開発 / 承認申請 / 承認取得 biotoday@biotoday.com Tue, 01 Sep 2026 15:01:29 +0900 http://www.biotoday.com/post_comment.cfm?init=A110563&ref=rss [企業] 甲状腺刺激ホルモン受容体を活性化する自己抗体の排除薬のMerida社をLillyが買う http://www.biotoday.com/view.cfm?n=110562&ref=rss http://www.biotoday.com/view.cfm?n=110562&ref=rss ビジネス / 対外交渉 / 合併/買収 biotoday@biotoday.com Tue, 01 Sep 2026 14:20:10 +0900 http://www.biotoday.com/post_comment.cfm?init=A110562&ref=rss [企業] AstraZenecaのレラキシン受容体活性化薬が心不全Ph2b試験で効果あり http://www.biotoday.com/view.cfm?n=110561&ref=rss http://www.biotoday.com/view.cfm?n=110561&ref=rss 開発 / 臨床試験 / 第2相試験 biotoday@biotoday.com Tue, 01 Sep 2026 13:11:39 +0900 http://www.biotoday.com/post_comment.cfm?init=A110561&ref=rss [医学] CytokineticsのMyqorzoが非閉塞性肥大型心筋症患者の身になったPh3試験論文 http://www.biotoday.com/view.cfm?n=110560&ref=rss http://www.biotoday.com/view.cfm?n=110560&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Tue, 01 Sep 2026 09:57:51 +0900 http://www.biotoday.com/post_comment.cfm?init=A110560&ref=rss [医学] 70歳以上高齢者がスタチンを服用しても体の不自由なく生きられる期間延長せず http://www.biotoday.com/view.cfm?n=110559&ref=rss http://www.biotoday.com/view.cfm?n=110559&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Tue, 01 Sep 2026 09:36:21 +0900 http://www.biotoday.com/post_comment.cfm?init=A110559&ref=rss [医学] 感染性心内膜炎の抗生剤治療はなんなら2-4週間で事足りうる http://www.biotoday.com/view.cfm?n=110558&ref=rss http://www.biotoday.com/view.cfm?n=110558&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Tue, 01 Sep 2026 08:49:15 +0900 http://www.biotoday.com/post_comment.cfm?init=A110558&ref=rss [医学] 脳卒中を若干生じ易い心房細動患者の一大事が凝固因子直撃経口抗凝固薬で減少 http://www.biotoday.com/view.cfm?n=110557&ref=rss http://www.biotoday.com/view.cfm?n=110557&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Tue, 01 Sep 2026 07:58:15 +0900 http://www.biotoday.com/post_comment.cfm?init=A110557&ref=rss [医学] 急性冠症候群患者に第XIa因子阻害薬milvexianの取り柄なしだったPh3試験論文 http://www.biotoday.com/view.cfm?n=110556&ref=rss http://www.biotoday.com/view.cfm?n=110556&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 16:52:25 +0900 http://www.biotoday.com/post_comment.cfm?init=A110556&ref=rss [医学] ACS患者のプラスグレル治療方針で死亡、心筋梗塞、脳卒中はより減らず http://www.biotoday.com/view.cfm?n=110555&ref=rss http://www.biotoday.com/view.cfm?n=110555&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 16:30:56 +0900 http://www.biotoday.com/post_comment.cfm?init=A110555&ref=rss [医学] STEMI患者のPCI前から1年間のプラスグレル単独がアスピリン併用に比肩せず http://www.biotoday.com/view.cfm?n=110554&ref=rss http://www.biotoday.com/view.cfm?n=110554&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 15:52:27 +0900 http://www.biotoday.com/post_comment.cfm?init=A110554&ref=rss [医学] ステント留置1年経過患者の2年間のクロピドグレル単独がアスピリン併用に比肩 http://www.biotoday.com/view.cfm?n=110553&ref=rss http://www.biotoday.com/view.cfm?n=110553&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 14:53:47 +0900 http://www.biotoday.com/post_comment.cfm?init=A110553&ref=rss [医学] 血管造影から推定したFFR利用のSTEMI患者多枝病変一揃いPCIが有益 http://www.biotoday.com/view.cfm?n=110552&ref=rss http://www.biotoday.com/view.cfm?n=110552&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 13:50:57 +0900 http://www.biotoday.com/post_comment.cfm?init=A110552&ref=rss [医学] 心筋梗塞ではないが急性冠症候群かもしれない救急科患者のCT冠動脈造影が無益 http://www.biotoday.com/view.cfm?n=110551&ref=rss http://www.biotoday.com/view.cfm?n=110551&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 09:45:31 +0900 http://www.biotoday.com/post_comment.cfm?init=A110551&ref=rss [医学] 心不全と左心疾患と関連する肺高血圧症の肺動脈神経除去治療が有益 http://www.biotoday.com/view.cfm?n=110550&ref=rss http://www.biotoday.com/view.cfm?n=110550&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 08:45:30 +0900 http://www.biotoday.com/post_comment.cfm?init=A110550&ref=rss [医学] TAVI先がPCI先に劣らず〜どっちを先にするかは患者毎に決めたらいい http://www.biotoday.com/view.cfm?n=110549&ref=rss http://www.biotoday.com/view.cfm?n=110549&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 08:12:44 +0900 http://www.biotoday.com/post_comment.cfm?init=A110549&ref=rss [医学] 心不全患者の重度三尖弁逆流の経カテーテル三尖弁修復が内科治療に勝る http://www.biotoday.com/view.cfm?n=110548&ref=rss http://www.biotoday.com/view.cfm?n=110548&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Mon, 31 Aug 2026 07:03:07 +0900 http://www.biotoday.com/post_comment.cfm?init=A110548&ref=rss [企業] 破産のBioXcel社の神経分野製品の取得にまずTevaが名乗りを上げた http://www.biotoday.com/view.cfm?n=110547&ref=rss http://www.biotoday.com/view.cfm?n=110547&ref=rss ビジネス / 対外交渉 / ライセンス biotoday@biotoday.com Sun, 30 Aug 2026 16:15:09 +0900 http://www.biotoday.com/post_comment.cfm?init=A110547&ref=rss [企業] BioNTech/RocheのmRNAワクチンの大腸癌切除後投与Ph2試験打ち切り http://www.biotoday.com/view.cfm?n=110546&ref=rss http://www.biotoday.com/view.cfm?n=110546&ref=rss 開発 / 臨床試験 / 中止 || 開発 / 臨床試験 / 第2相試験 biotoday@biotoday.com Sun, 30 Aug 2026 15:20:31 +0900 http://www.biotoday.com/post_comment.cfm?init=A110546&ref=rss [企業] AusperBioがPh3試験中の慢性B型肝炎薬の開発資金1億2000万ドル調達 http://www.biotoday.com/view.cfm?n=110545&ref=rss http://www.biotoday.com/view.cfm?n=110545&ref=rss ビジネス / ファイナンス / 投資/融資 biotoday@biotoday.com Sun, 30 Aug 2026 13:47:54 +0900 http://www.biotoday.com/post_comment.cfm?init=A110545&ref=rss [医学] AstraZenecaのWainuaがアミロイド心筋症に歯が立たなかったPh3試験結果報告 http://www.biotoday.com/view.cfm?n=110544&ref=rss http://www.biotoday.com/view.cfm?n=110544&ref=rss ジャーナル / 総合医学誌 / New England Journal of Medicine（NEJM） biotoday@biotoday.com Sun, 30 Aug 2026 12:24:32 +0900 http://www.biotoday.com/post_comment.cfm?init=A110544&ref=rss [企業] Rocheが中国のDualityBio社と組んで癌を治療する弾込め抗体（ADC）に取り組む http://www.biotoday.com/view.cfm?n=110543&ref=rss http://www.biotoday.com/view.cfm?n=110543&ref=rss ビジネス / 対外交渉 / 企業間提携 biotoday@biotoday.com Sun, 30 Aug 2026 09:52:09 +0900 http://www.biotoday.com/post_comment.cfm?init=A110543&ref=rss [企業] Lillyの2型糖尿病薬Mounjaroを心血管一大事予防を目当てに使うことを米国承認 http://www.biotoday.com/view.cfm?n=110542&ref=rss http://www.biotoday.com/view.cfm?n=110542&ref=rss 開発 / 承認申請 / 承認取得 biotoday@biotoday.com Sun, 30 Aug 2026 09:29:55 +0900 http://www.biotoday.com/post_comment.cfm?init=A110542&ref=rss [企業] 真性多血症を治療する武田薬品のヘプシジン模倣環状ペプチド薬Mimrylo米国承認 http://www.biotoday.com/view.cfm?n=110541&ref=rss http://www.biotoday.com/view.cfm?n=110541&ref=rss 開発 / 承認申請 / 承認取得 biotoday@biotoday.com Sun, 30 Aug 2026 07:52:54 +0900 http://www.biotoday.com/post_comment.cfm?init=A110541&ref=rss [医学] MLC1抗体に起因するNMOSD様の炎症性脳疾患があるらしい http://www.biotoday.com/view.cfm?n=110540&ref=rss http://www.biotoday.com/view.cfm?n=110540&ref=rss biotoday@biotoday.com Sat, 29 Aug 2026 17:02:15 +0900 http://www.biotoday.com/post_comment.cfm?init=A110540&ref=rss [医学] 脂肪酸輸送体CD36阻害で非小細胞肺癌（NSCLC）の膜軟髄膜転移を防ぎうる http://www.biotoday.com/view.cfm?n=110539&ref=rss http://www.biotoday.com/view.cfm?n=110539&ref=rss biotoday@biotoday.com Sat, 29 Aug 2026 16:15:18 +0900 http://www.biotoday.com/post_comment.cfm?init=A110539&ref=rss [医学] 原発性アルドステロン症では睡眠中に副腎ステロイド過剰分泌が繰り返される http://www.biotoday.com/view.cfm?n=110538&ref=rss http://www.biotoday.com/view.cfm?n=110538&ref=rss biotoday@biotoday.com Sat, 29 Aug 2026 16:08:08 +0900 http://www.biotoday.com/post_comment.cfm?init=A110538&ref=rss [医学] LTBP4欠乏がMRC1+/CD44+マクロファージを生んで大腸癌を進展させる http://www.biotoday.com/view.cfm?n=110537&ref=rss http://www.biotoday.com/view.cfm?n=110537&ref=rss biotoday@biotoday.com Sat, 29 Aug 2026 16:05:22 +0900 http://www.biotoday.com/post_comment.cfm?init=A110537&ref=rss [医学] 単球のインターフェロン反応が高い人にmRNAワクチンの副作用が生じ易い http://www.biotoday.com/view.cfm?n=110536&ref=rss http://www.biotoday.com/view.cfm?n=110536&ref=rss biotoday@biotoday.com Sat, 29 Aug 2026 15:56:21 +0900 http://www.biotoday.com/post_comment.cfm?init=A110536&ref=rss [医学] 尿路感染症妊婦の早産をIL-10で防ぎうる http://www.biotoday.com/view.cfm?n=110535&ref=rss http://www.biotoday.com/view.cfm?n=110535&ref=rss biotoday@biotoday.com Sat, 29 Aug 2026 15:14:04 +0900 http://www.biotoday.com/post_comment.cfm?init=A110535&ref=rss [医学] バッテン病の類いのCLN3病の網膜変性を酸性セラミダーゼ補充で抑制しうる http://www.biotoday.com/view.cfm?n=110534&ref=rss http://www.biotoday.com/view.cfm?n=110534&ref=rss biotoday@biotoday.com Fri, 28 Aug 2026 16:42:40 +0900 http://www.biotoday.com/post_comment.cfm?init=A110534&ref=rss [医学] Scarb1遺伝子からのSR-BI発現回復でイノシンが後ろ盾の脂肪分解が復活しうる http://www.biotoday.com/view.cfm?n=110533&ref=rss http://www.biotoday.com/view.cfm?n=110533&ref=rss biotoday@biotoday.com Fri, 28 Aug 2026 15:30:34 +0900 http://www.biotoday.com/post_comment.cfm?init=A110533&ref=rss [企業] Osivax社がGC社の手持ちと組み合わせたインフルエンザワクチンを開発する http://www.biotoday.com/view.cfm?n=110532&ref=rss http://www.biotoday.com/view.cfm?n=110532&ref=rss ビジネス / 対外交渉 / 企業間提携 biotoday@biotoday.com Fri, 28 Aug 2026 11:28:32 +0900 http://www.biotoday.com/post_comment.cfm?init=A110532&ref=rss [企業] エジプトのMinapharm社のブンディブギョワクチンにCEPIが最大1650万ドル提供 http://www.biotoday.com/view.cfm?n=110531&ref=rss http://www.biotoday.com/view.cfm?n=110531&ref=rss ビジネス / ファイナンス / 投資/融資 biotoday@biotoday.com Fri, 28 Aug 2026 09:39:37 +0900 http://www.biotoday.com/post_comment.cfm?init=A110531&ref=rss [医学] Lillyの肥満薬Zepbound使用と医療費が少なくて済むことが関連 http://www.biotoday.com/view.cfm?n=110530&ref=rss http://www.biotoday.com/view.cfm?n=110530&ref=rss 開発 / 臨床試験 / その他臨床試験 biotoday@biotoday.com Fri, 28 Aug 2026 08:54:32 +0900 http://www.biotoday.com/post_comment.cfm?init=A110530&ref=rss [企業] Gileadの1日1回経口服用HIV薬Bixlenvo（bictegravir/lenacapavir）を米国承認 http://www.biotoday.com/view.cfm?n=110529&ref=rss http://www.biotoday.com/view.cfm?n=110529&ref=rss 開発 / 承認申請 / 承認取得 biotoday@biotoday.com Fri, 28 Aug 2026 08:30:20 +0900 http://www.biotoday.com/post_comment.cfm?init=A110529&ref=rss [企業] Priovantの経口の皮膚筋炎（DM）薬Lisraya/リスラヤを米国承認 http://www.biotoday.com/view.cfm?n=110528&ref=rss http://www.biotoday.com/view.cfm?n=110528&ref=rss 開発 / 承認申請 / 承認取得 biotoday@biotoday.com Fri, 28 Aug 2026 08:11:50 +0900 http://www.biotoday.com/post_comment.cfm?init=A110528&ref=rss [企業] Amgen/AstraZenecaの抗TSLP抗体Tezspireの好酸球性食道炎Ph3試験成功 http://www.biotoday.com/view.cfm?n=110527&ref=rss http://www.biotoday.com/view.cfm?n=110527&ref=rss 開発 / 臨床試験 / 第3相/ピボタル試験 biotoday@biotoday.com Thu, 27 Aug 2026 16:20:03 +0900 http://www.biotoday.com/post_comment.cfm?init=A110527&ref=rss [医学] GSKの帯状疱疹ワクチンShingrixと心血管疾患生じ難くなることが関連 http://www.biotoday.com/view.cfm?n=110526&ref=rss http://www.biotoday.com/view.cfm?n=110526&ref=rss biotoday@biotoday.com Thu, 27 Aug 2026 13:14:35 +0900 http://www.biotoday.com/post_comment.cfm?init=A110526&ref=rss [企業] Akeso/Summitのivonescimab込み胆道癌初治療が中国でのPh3試験で生存改善達成 http://www.biotoday.com/view.cfm?n=110525&ref=rss http://www.biotoday.com/view.cfm?n=110525&ref=rss 開発 / 臨床試験 / 第3相/ピボタル試験 biotoday@biotoday.com Thu, 27 Aug 2026 11:25:15 +0900 http://www.biotoday.com/post_comment.cfm?init=A110525&ref=rss [企業] 韓国のSK社がBiohaven社のPh2/3試験段階のてんかん薬opakalimを手に入れる http://www.biotoday.com/view.cfm?n=110524&ref=rss http://www.biotoday.com/view.cfm?n=110524&ref=rss ビジネス / 対外交渉 / ライセンス biotoday@biotoday.com Thu, 27 Aug 2026 10:00:14 +0900 http://www.biotoday.com/post_comment.cfm?init=A110524&ref=rss [医学] 【増補版】メトホルミン使用と認知症リスク低下が無作為化試験長期追跡で関連 http://www.biotoday.com/view.cfm?n=110523&ref=rss http://www.biotoday.com/view.cfm?n=110523&ref=rss biotoday@biotoday.com Thu, 27 Aug 2026 09:39:36 +0900 http://www.biotoday.com/post_comment.cfm?init=A110523&ref=rss [企業] Spyreの抗TL1A抗体SPY072のPh2試験での関節リウマチ治療効果が期待外れ http://www.biotoday.com/view.cfm?n=110522&ref=rss http://www.biotoday.com/view.cfm?n=110522&ref=rss 開発 / 臨床試験 / 第2相試験 biotoday@biotoday.com Thu, 27 Aug 2026 09:34:35 +0900 http://www.biotoday.com/post_comment.cfm?init=A110522&ref=rss [企業] 膵癌を治療するRevolutionの活性化KRAS阻害薬Rasonque/ラソンクを米国承認 http://www.biotoday.com/view.cfm?n=110521&ref=rss http://www.biotoday.com/view.cfm?n=110521&ref=rss 開発 / 承認申請 / 承認取得 biotoday@biotoday.com Thu, 27 Aug 2026 08:51:38 +0900 http://www.biotoday.com/post_comment.cfm?init=A110521&ref=rss [医学] 心筋梗塞後に作られる冠動脈が動脈ではなく毛細血管を端緒とすることが判明 http://www.biotoday.com/view.cfm?n=110520&ref=rss http://www.biotoday.com/view.cfm?n=110520&ref=rss biotoday@biotoday.com Thu, 27 Aug 2026 08:29:09 +0900 http://www.biotoday.com/post_comment.cfm?init=A110520&ref=rss [医学] パン酵母を使ってインフルエンザワクチンを作る技術を開発 http://www.biotoday.com/view.cfm?n=110519&ref=rss http://www.biotoday.com/view.cfm?n=110519&ref=rss 技術 / 製剤技術 / 全般 biotoday@biotoday.com Thu, 27 Aug 2026 07:11:49 +0900 http://www.biotoday.com/post_comment.cfm?init=A110519&ref=rss [企業] Jazz社のHER2標的薬Ziiheraの胃癌治療2通りを米国承認 http://www.biotoday.com/view.cfm?n=110518&ref=rss http://www.biotoday.com/view.cfm?n=110518&ref=rss 開発 / 承認申請 / 承認取得 biotoday@biotoday.com Thu, 27 Aug 2026 06:53:22 +0900 http://www.biotoday.com/post_comment.cfm?init=A110518&ref=rss [企業] 温式自己免疫性溶血性貧血へのJ&JのImaavy/アイマービー使用を米国承認 http://www.biotoday.com/view.cfm?n=110517&ref=rss http://www.biotoday.com/view.cfm?n=110517&ref=rss 開発 / 承認申請 / 承認取得 biotoday@biotoday.com Wed, 26 Aug 2026 16:35:12 +0900 http://www.biotoday.com/post_comment.cfm?init=A110517&ref=rss [企業] Bausch + Lombのドライアイ薬2つ組み合わせがPh2試験失敗でもPh3試験に進む http://www.biotoday.com/view.cfm?n=110516&ref=rss http://www.biotoday.com/view.cfm?n=110516&ref=rss 開発 / 臨床試験 / 第3相/ピボタル試験 biotoday@biotoday.com Wed, 26 Aug 2026 14:06:06 +0900 http://www.biotoday.com/post_comment.cfm?init=A110516&ref=rss [医学] コーヒーをよく飲むことと血中の分枝鎖アミノ酸（BCAA）が少ないことが関連 http://www.biotoday.com/view.cfm?n=110515&ref=rss http://www.biotoday.com/view.cfm?n=110515&ref=rss biotoday@biotoday.com Tue, 25 Aug 2026 16:30:18 +0900 http://www.biotoday.com/post_comment.cfm?init=A110515&ref=rss